Cargando…
Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment
Myeloid and lymphoid neoplasms with eosinophilia and FGFR1 rearrangements (MLN-eo FGFR1) disease is derived from a pluripotent hematopoietic stem cell and has a complex presentation with a myeloproliferative disorder with or without eosinophilia and frequently presents with mixed lineage T- or B-lym...
Autores principales: | Cowell, John K., Hu, Tianxiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8562765/ https://www.ncbi.nlm.nih.gov/pubmed/34734169 http://dx.doi.org/10.20517/cdr.2021.30 |
Ejemplares similares
-
Downregulation of PUMA underlies resistance to FGFR1 inhibitors in the stem cell leukemia/lymphoma syndrome
por: Liu, Yun, et al.
Publicado: (2020) -
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023) -
FGFR1 fusion kinase regulation of MYC expression drives development of stem cell leukemia/lymphoma syndrome
por: Hu, Tianxiang, et al.
Publicado: (2018) -
Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer
por: Weickhardt, Andrew J., et al.
Publicado: (2022) -
IRAK1-regulated IFN-γ signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies
por: Cai, Baohuan, et al.
Publicado: (2021)